a cdk9 Search Results


cdk9 inhibitors a 1592668  (AbbVie Inc)
90
AbbVie Inc cdk9 inhibitors a 1592668
Expression of BCL‐2 family proteins in MCL cell lines and their response to venetoclax or <t>CDK9</t> inhibitors. A, Immunoblotting assay of BCL‐2 family proteins utilizing β‐actin (ACTB) as a loading control. B, MCL cell lines were treated with indicated doses of A‐1467729, A‐1592668, or venetoclax for 5 h and apoptotic cells were determined by flow cytometry (Annexin‐V/7‐AAD positive population). Data are presented as the mean ± SEM of three independent experiments
Cdk9 Inhibitors A 1592668, supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cdk9 inhibitors a 1592668/product/AbbVie Inc
Average 90 stars, based on 1 article reviews
cdk9 inhibitors a 1592668 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
lentiviruses expressing a shrna targeting cdk9  (Shanghai Genechem Ltd)
90
Shanghai Genechem Ltd lentiviruses expressing a shrna targeting cdk9
CDK9 knockdown suppresses BLM-induced fibrotic marker levels in vitro . (A) Protein levels of CDK9, fibrotic markers and senescent markers by Western blots after knockdown of CDK9 with shCDK9 <t>lentivirus</t> in epithelial A549 cells. n = 4/group. (B) SA-β-gal activity staining with shCDK9 lentivirus transfection and (C) the quantification of SA-β-gal-positive cells. Scale bar: 100 μm. (D) SA-β-gal activity staining with CDK9 inhibitor AZD4573 treatment (1 µM) and (E) the quantification of SA-β-gal-positive cells. Scale bar: 100 μm. (F) Western blot analysis of CDK9, p-p53 and p21 in epithelial A549 cells. ** p < 0.01 compared with respective controls; ## p < 0.01, compared with BLM; 2-way ANOVA with a post hoc Tukey’s test. All data are presented as the mean ± SEM.
Lentiviruses Expressing A Shrna Targeting Cdk9, supplied by Shanghai Genechem Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviruses expressing a shrna targeting cdk9/product/Shanghai Genechem Ltd
Average 90 stars, based on 1 article reviews
lentiviruses expressing a shrna targeting cdk9 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Expression of BCL‐2 family proteins in MCL cell lines and their response to venetoclax or CDK9 inhibitors. A, Immunoblotting assay of BCL‐2 family proteins utilizing β‐actin (ACTB) as a loading control. B, MCL cell lines were treated with indicated doses of A‐1467729, A‐1592668, or venetoclax for 5 h and apoptotic cells were determined by flow cytometry (Annexin‐V/7‐AAD positive population). Data are presented as the mean ± SEM of three independent experiments

Journal: EJHaem

Article Title: Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma

doi: 10.1002/jha2.48

Figure Lengend Snippet: Expression of BCL‐2 family proteins in MCL cell lines and their response to venetoclax or CDK9 inhibitors. A, Immunoblotting assay of BCL‐2 family proteins utilizing β‐actin (ACTB) as a loading control. B, MCL cell lines were treated with indicated doses of A‐1467729, A‐1592668, or venetoclax for 5 h and apoptotic cells were determined by flow cytometry (Annexin‐V/7‐AAD positive population). Data are presented as the mean ± SEM of three independent experiments

Article Snippet: Venetoclax [ ], CDK9 inhibitors A‐1467729 and A‐1592668 [ ], dinaciclib, and MCL‐1 inhibitor A‐1210477 [ ] were obtained from AbbVie Inc. (North Chicago, IL).

Techniques: Expressing, Western Blot, Flow Cytometry

Combined effect of CDK9 inhibitor plus venetoclax or MCL‐1 inhibitor plus venetoclax in MCL cell lines. A, Venetoclax plus A‐1467729, A‐1592668, or A‐1210477 synergistically induces apoptosis in MCL cells. The four MCL cell lines were co‐treated with indicated inhibitors at the indicated concentrations for 5 h and apoptotic cells were determined by flow cytometry. Data are presented as the mean of three independent experiments with error bars indicating the SEM. Combination index (CI) plots are summarized in Figure S1. B, CDK9 inhibition reduces p‐RNA pol‐II (Ser2) and MCL‐1 expression to enhance venetoclax‐caused cleavage of PARP. Each cell lines were treated with venetoclax, A‐1467729, or venetoclax plus A‐1467729 at the indicated concentrations and times for 5 h and the impact on phospho‐RNA polymerase II (Ser2), total RNA polymerase II, PARP, BCL‐2, and MCL‐1 determined by western blot utilizing β‐actin (ACTB) as a loading control. C, Significant correlation ( P < .05) between CIs of venetoclax plus A‐1592668 and venetoclax plus A‐1210477 in tested JVM‐2 and CCMCL1 cell lines

Journal: EJHaem

Article Title: Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma

doi: 10.1002/jha2.48

Figure Lengend Snippet: Combined effect of CDK9 inhibitor plus venetoclax or MCL‐1 inhibitor plus venetoclax in MCL cell lines. A, Venetoclax plus A‐1467729, A‐1592668, or A‐1210477 synergistically induces apoptosis in MCL cells. The four MCL cell lines were co‐treated with indicated inhibitors at the indicated concentrations for 5 h and apoptotic cells were determined by flow cytometry. Data are presented as the mean of three independent experiments with error bars indicating the SEM. Combination index (CI) plots are summarized in Figure S1. B, CDK9 inhibition reduces p‐RNA pol‐II (Ser2) and MCL‐1 expression to enhance venetoclax‐caused cleavage of PARP. Each cell lines were treated with venetoclax, A‐1467729, or venetoclax plus A‐1467729 at the indicated concentrations and times for 5 h and the impact on phospho‐RNA polymerase II (Ser2), total RNA polymerase II, PARP, BCL‐2, and MCL‐1 determined by western blot utilizing β‐actin (ACTB) as a loading control. C, Significant correlation ( P < .05) between CIs of venetoclax plus A‐1592668 and venetoclax plus A‐1210477 in tested JVM‐2 and CCMCL1 cell lines

Article Snippet: Venetoclax [ ], CDK9 inhibitors A‐1467729 and A‐1592668 [ ], dinaciclib, and MCL‐1 inhibitor A‐1210477 [ ] were obtained from AbbVie Inc. (North Chicago, IL).

Techniques: Flow Cytometry, Inhibition, Expressing, Western Blot

Interactions of venetoclax plus CDK9 inhibitors or venetoclax plus MCL‐1 inhibitor in primary MCL cells. A, Primary MCL cells were co‐treated for 5 h with venetoclax plus A‐1467729; venetoclax plus A‐1592668 or venetoclax plus A‐1210477 at the indicated concentrations and the effect on apoptosis was determined by flow cytometry. B, Significant correlation of CIs between venetoclax plus A‐1592668 and venetoclax plus A‐1210477 were subsequently determined ( P < .01). C, A‐1467729 reduces p‐RNA pol‐II (Ser‐2) and MCL‐1 expression in primary MCL cells (case 2). Immunoblotting of phospho‐RNA pol‐II (Ser2), total RNA pol‐II, MCL‐1, BCL‐2, and β‐actin (ACTB) were performed after treatment without or with A‐1467729 (5 nM), venetoclax (0.5 nM), or their combination for 5 h. The densitometries of phospho‐RNA pol‐II (Ser2) bands or MCL‐1 bands were normalized with total RNA Pol‐II or with ACTB, respectively

Journal: EJHaem

Article Title: Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma

doi: 10.1002/jha2.48

Figure Lengend Snippet: Interactions of venetoclax plus CDK9 inhibitors or venetoclax plus MCL‐1 inhibitor in primary MCL cells. A, Primary MCL cells were co‐treated for 5 h with venetoclax plus A‐1467729; venetoclax plus A‐1592668 or venetoclax plus A‐1210477 at the indicated concentrations and the effect on apoptosis was determined by flow cytometry. B, Significant correlation of CIs between venetoclax plus A‐1592668 and venetoclax plus A‐1210477 were subsequently determined ( P < .01). C, A‐1467729 reduces p‐RNA pol‐II (Ser‐2) and MCL‐1 expression in primary MCL cells (case 2). Immunoblotting of phospho‐RNA pol‐II (Ser2), total RNA pol‐II, MCL‐1, BCL‐2, and β‐actin (ACTB) were performed after treatment without or with A‐1467729 (5 nM), venetoclax (0.5 nM), or their combination for 5 h. The densitometries of phospho‐RNA pol‐II (Ser2) bands or MCL‐1 bands were normalized with total RNA Pol‐II or with ACTB, respectively

Article Snippet: Venetoclax [ ], CDK9 inhibitors A‐1467729 and A‐1592668 [ ], dinaciclib, and MCL‐1 inhibitor A‐1210477 [ ] were obtained from AbbVie Inc. (North Chicago, IL).

Techniques: Flow Cytometry, Expressing, Western Blot

The combination of venetoclax with CDK9 inhibitors provides added benefit over either agent alone in a xenograft model of MCL. NSG mice bearing engrafted Jeko‐1 cells were treated with A‐1592668 (4 mg/kg, twice a week with oral gavage), dinaciclib (30 mg/kg, twice a week with intraperitoneal injection), venetoclax (50 mg/kg, everyday with oral gavage), or venetoclax in combination with A‐1592668 or dinaciclib, and the diameters of subcutaneous tumors were measured. Data are presented as the mean tumor volume ± SEM obtained from six mice per treatment group. Venetoclax treated mice had less tumor burden than vehicle arm on day 28 or later ( P < .05). A‐1592668, dinaciclib, or their combinations with venetoclax significantly reduced the tumor burden compared with control mice with P ‐values of .024, .001, < .001, and < .001, respectively. Venetoclax plus A‐1592668 or dinaciclib further minimize the tumor volumes than A‐1592668 or dinaciclib alone with P ‐values of .0014 and .0048, respectively. There was no significant difference between A‐1592668 and dinaciclib ( P = .50) or between venetoclax plus A‐1592668 versus venetoclax plus dinaciclib ( P = .23).

Journal: EJHaem

Article Title: Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma

doi: 10.1002/jha2.48

Figure Lengend Snippet: The combination of venetoclax with CDK9 inhibitors provides added benefit over either agent alone in a xenograft model of MCL. NSG mice bearing engrafted Jeko‐1 cells were treated with A‐1592668 (4 mg/kg, twice a week with oral gavage), dinaciclib (30 mg/kg, twice a week with intraperitoneal injection), venetoclax (50 mg/kg, everyday with oral gavage), or venetoclax in combination with A‐1592668 or dinaciclib, and the diameters of subcutaneous tumors were measured. Data are presented as the mean tumor volume ± SEM obtained from six mice per treatment group. Venetoclax treated mice had less tumor burden than vehicle arm on day 28 or later ( P < .05). A‐1592668, dinaciclib, or their combinations with venetoclax significantly reduced the tumor burden compared with control mice with P ‐values of .024, .001, < .001, and < .001, respectively. Venetoclax plus A‐1592668 or dinaciclib further minimize the tumor volumes than A‐1592668 or dinaciclib alone with P ‐values of .0014 and .0048, respectively. There was no significant difference between A‐1592668 and dinaciclib ( P = .50) or between venetoclax plus A‐1592668 versus venetoclax plus dinaciclib ( P = .23).

Article Snippet: Venetoclax [ ], CDK9 inhibitors A‐1467729 and A‐1592668 [ ], dinaciclib, and MCL‐1 inhibitor A‐1210477 [ ] were obtained from AbbVie Inc. (North Chicago, IL).

Techniques: Injection

CDK9 knockdown suppresses BLM-induced fibrotic marker levels in vitro . (A) Protein levels of CDK9, fibrotic markers and senescent markers by Western blots after knockdown of CDK9 with shCDK9 lentivirus in epithelial A549 cells. n = 4/group. (B) SA-β-gal activity staining with shCDK9 lentivirus transfection and (C) the quantification of SA-β-gal-positive cells. Scale bar: 100 μm. (D) SA-β-gal activity staining with CDK9 inhibitor AZD4573 treatment (1 µM) and (E) the quantification of SA-β-gal-positive cells. Scale bar: 100 μm. (F) Western blot analysis of CDK9, p-p53 and p21 in epithelial A549 cells. ** p < 0.01 compared with respective controls; ## p < 0.01, compared with BLM; 2-way ANOVA with a post hoc Tukey’s test. All data are presented as the mean ± SEM.

Journal: Frontiers in Pharmacology

Article Title: Wogonin protects against bleomycin-induced mouse pulmonary fibrosis via the inhibition of CDK9/p53-mediated cell senescence

doi: 10.3389/fphar.2024.1407891

Figure Lengend Snippet: CDK9 knockdown suppresses BLM-induced fibrotic marker levels in vitro . (A) Protein levels of CDK9, fibrotic markers and senescent markers by Western blots after knockdown of CDK9 with shCDK9 lentivirus in epithelial A549 cells. n = 4/group. (B) SA-β-gal activity staining with shCDK9 lentivirus transfection and (C) the quantification of SA-β-gal-positive cells. Scale bar: 100 μm. (D) SA-β-gal activity staining with CDK9 inhibitor AZD4573 treatment (1 µM) and (E) the quantification of SA-β-gal-positive cells. Scale bar: 100 μm. (F) Western blot analysis of CDK9, p-p53 and p21 in epithelial A549 cells. ** p < 0.01 compared with respective controls; ## p < 0.01, compared with BLM; 2-way ANOVA with a post hoc Tukey’s test. All data are presented as the mean ± SEM.

Article Snippet: Lentiviruses expressing a shRNA targeting CDK9 (Gene ID: 1025), which a short hairpin sequence targeting against CDK9 (shCDK9) was GGGAGAUCAAGAUCCUUCATT, or a scramble control (shNC): TTCTCCGAACGTGTCACGT, were generated by Shanghai GeneChem Co., Ltd. (Shanghai, China).

Techniques: Knockdown, Marker, In Vitro, Western Blot, Activity Assay, Staining, Transfection